Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A rare inflammatory multisystem disorder characterized clinically by fever of unknown origin, arthralgia or arthritis, hyperleucocytosis, and typical skin rash.
Biomarker and diagnostic research for adult-onset Still disease has been reported in the published literature.
2 FDA-approved treatments are available for adult-onset Still disease, including CANAKINUMAB (ILARIS, approved 2009) and ANAKINRA (KINERET, approved 2001). 1 additional treatment is recommended by clinical guidelines. An additional 2 compounds hold orphan drug designation.
Brand Name | Generic Name | Mechanism | Approved |
|---|
Estimated prevalence: 1-9 in 100,000 (Uncommon).
3 clinical trials registered, 2 recruiting. Interventions under study include other interventions and drug therapy. Pipeline includes 1 NA. Research is sponsored by a mix of industry and academic institutions.
137 publications have been identified in PubMed for adult-onset Still disease. Kisho has analyzed 40 by research type. Research spans Case Report / Case Series (35%), Epidemiology / Natural History (23%), and Review / Meta-Analysis (15%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 14 |
Data assembled from 5 of 12 sources · Last updated Nov 4, 2026, 10:15 AM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Common questions about adult-onset Still disease
ILARIS | CANAKINUMAB | — | 2009 | Available |
KINERET | ANAKINRA | — | 2001 | Available |
The following drugs are recommended by published clinical guidelines for adult-onset Still disease, though they may not carry a specific FDA approval for this indication. Treatment decisions should be made with a specialist.
Brand Name | Generic Name | Mechanism | Market Status |
|---|---|---|---|
ACTEMRA | TOCILIZUMAB | — | Available |
The following drugs have received orphan drug designation from the FDA for adult-onset Still disease. Orphan designation reflects regulatory interest and does not indicate approval for treatment.
Brand Name | Generic Name | Sponsor | Designated | Exclusivity End | Designation Status |
|---|---|---|---|---|---|
tadekinig alfa | tadekinig alfa | AB2 Bio Ltd | 2017 | — | Designated |
Interleukin-1 Trap | Interleukin-1 Trap | Regeneron Pharmaceuticals, Inc. | 2005 | — | Designated |
3 trials found
35%
Disease patterns and progression | 9 | 23% |
Research summaries | 6 | 15% |
Testing and diagnosis research | 3 | 8% |
Clinical study results | 3 | 8% |
Laboratory research | 3 | 8% |
Other research | 2 | 5% |
Thiele K (2026). [PMID: 41412093](https://pubmed.ncbi.nlm.nih.gov/41412093/). *Semin Arthritis Rheum*. [Epidemiology / Natural History]
Mueller YM (2026). [PMID: 41728940](https://pubmed.ncbi.nlm.nih.gov/41728940/). *Arthritis & rheumatology (Hoboken, N.J.)*. [Clinical Trial Publication]
Cognacq G (2026). [PMID: 41985135](https://pubmed.ncbi.nlm.nih.gov/41985135/). *N Engl J Med*. [Case Report / Case Series]
Balay-Dustrude E (2026). [PMID: 41033820](https://pubmed.ncbi.nlm.nih.gov/41033820/). *J Rheumatol*. [Review / Meta-Analysis]
Lakhani HA (2026). [PMID: 41658735](https://pubmed.ncbi.nlm.nih.gov/41658735/). *Cureus*. [Review / Meta-Analysis]
Kobrin DM (2026). [PMID: 41397865](https://pubmed.ncbi.nlm.nih.gov/41397865/). *J Rheumatol*. [Basic Science / Preclinical]
Li J (2026). [PMID: 41692495](https://pubmed.ncbi.nlm.nih.gov/41692495/). *J Rheumatol*. [Other]
Gomes C (2026). [PMID: 41853279](https://pubmed.ncbi.nlm.nih.gov/41853279/). *Front Immunol*. [Case Report / Case Series]
Najeeb A (2026). [PMID: 41737969](https://pubmed.ncbi.nlm.nih.gov/41737969/). *Clin Case Rep*. [Case Report / Case Series]
Lim DZJ (2025). [PMID: 41035843](https://pubmed.ncbi.nlm.nih.gov/41035843/). *Skin Health Dis*. [Case Report / Case Series]
AI-curated news mentioning adult-onset Still disease
Updated Oct 30, 2026
still s disease and malignancies insights into the balance between inflammatory enhancement and immune control data from the international aida network still s disease registry
A recent case study highlights a flare of adult-onset Still disease occurring five days after a poly-l-lactic acid injection, raising concerns for aesthetic practices. This finding underscores the need for caution when administering aesthetic treatments to patients with underlying autoimmune conditions.
A recent autopsy case report highlights secondary pulmonary alveolar proteinosis that mimicked the progression of interstitial lung disease in a patient undergoing treatment for adult-onset Still's disease. This finding underscores the need for careful differential diagnosis in similar clinical scenarios.